Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2022 16:01 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference

SAN DIEGO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines...
March 21, 2022 16:01 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
March 03, 2022 16:05 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
January 05, 2022 08:30 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
November 17, 2021 08:30 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
November 11, 2021 08:30 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
November 04, 2021 16:05 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a...
November 02, 2021 08:30 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces Steven W. Spector Joins the Company as General Counsel

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
September 21, 2021 08:30 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
September 08, 2021 07:00 ET | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right